Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Myeloid Derived Suppressor Cell Kinetics in Peripheral Blood Correlate with Efficacy and Toxicity of CAR T Cell Therapy in Relapsed or Refractory B Cell Lymphoma

David M Foureau, Hamid Ehsan, Fei Guo, Tahj Jones, Ryan W Jacobs, Bei Hu, Tamara K. Moyo, Yifan Pang, Steven I. Park, Lawrence J. Druhan, Ariel Bell, Nilanjan Ghosh

Blood (2023) 142 (Supplement 1): 1640.

https://doi.org/10.1182/blood-2023-187085

Published: 2023

Journal Articles

The Novel CDK9/CDK4/6/PI3K Triple Inhibitor LCI139 for the Treatment of MYC -Driven Mantle Cell Lymphoma

Dhananjaya Pal, Page Mangum Arditti, Krishnaiah Maddeboina, Cody C. McHale, Hsih-Te Yang, Bharath Yada, Hailey Lynn Dryden, David M Foureau, Donald L. Durden

Blood (2023) 142 (Supplement 1): 4180.

https://doi.org/10.1182/blood-2023-190023

Published: 2023

Journal Articles

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Manisha Bhutani, Myra Robinson, Barry Paul, Shebli Atrash, Cindy Varga, Xhevahire Begic, David M Foureau, Mauricio Pineda-Roman, Brinda Koya, Sarah Norek, Sara A Sutton, Michelle B Anderson, Donna Acampora, James T Symanowski, Peter M. Voorhees, Saad Usmani

Blood (2022) 140 (Supplement 1): 4440–4441.

https://doi.org/10.1182/blood-2022-160204

Published: 2022

Journal Articles

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Blood (2022) 140 (Supplement 1): 4393–4395.

https://doi.org/10.1182/blood-2022-160071

Published: 2022

Journal Articles

Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study

Aleksander L. Chojecki, Jai N. Patel, David M Foureau, James Symanowski, Xhevahire Begic, Michael Davis, Nury M Steuerwald, Sarah Norek, Srinivasa Reddy R. Sanikommu, Nilay A. Shah, Brittany Knick Ragon, Thomas G. Knight, Jing Ai, Michael R. Grunwald, Nilanjan Ghosh, Lawrence J Druhan, Belinda R. Avalos, Edward A. Copelan

Blood (2022) 140 (Supplement 1): 10534–10536.

https://doi.org/10.1182/blood-2022-160214

Published: 2022

Journal Articles

Aurora Kinase Inhibition Overcomes Primary Venetoclax Failure and Leads to Synthetic Lethality in BCL2-Positive Lymphomas Via Upregulation of P53/P21/BAX Axis

Rajeswaran Mani, Samon Benrashid, Sarah E Teague, Scott C Jaros, Hsih-Te Yang, Lawrence J Druhan, David M Foureau, Nury M Steuerwald, Nilanjan Ghosh, Edward A. Copelan, Donald L. Durden, Belinda Avalos, Steven I. Park

Blood (2021) 138 (Supplement 1): 682.

https://doi.org/10.1182/blood-2021-146064

Published: 2021

Journal Articles

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Manisha Bhutani, Myra Robinson, Shebli Atrash, David M Foureau, Katherine Rigby, Reed Friend, Barry Paul, James T Symanowski, Lawrence J Druhan, Sarah Norek, Mallory Tucker, Mauricio Pineda-Roman, Peter M. Voorhees, Saad Z. Usmani

Blood (2021) 138 (Supplement 1): 2739.

https://doi.org/10.1182/blood-2021-148508

Published: 2021

Journal Articles

Central Memory T-Cell Differentiation Correlates with Depth of Response in Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone (Elo-KRd)

David M Foureau, Manisha Bhutani, Fei Guo, Kateryna Fesenkova, Shebli Atrash, Reed Friend, Barry Paul, Myra M Robinson, James T Symanowski, Lawrence J Druhan, Mauricio Pineda-Roman, Peter M. Voorhees, Saad Z. Usmani

Blood (2021) 138 (Supplement 1): 1585.

https://doi.org/10.1182/blood-2021-152505

Published: 2021

Journal Articles

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Manisha Bhutani, MD, Monika House, RN, BA, Jiaxian He, MS, Shebli Atrash, David M Foureau, PhD, Barry Paul, MDMS, Reed Friend, MD, James T Symanowski, PhD, Sarah Norek, BSN, RN, Xhevahire Begic, MSPH, Donna Acampora, BSN, RN, Katherine K Farmer, BA, Carrie Ann Syfert, BSN, RN, Mauricio Pineda-Roman, MD, Peter Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-138485

Published: 2020

Journal Articles

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Shebli Atrash, MD, Myra Robinson, MSPH, Barry Paul, MDMS, Sarah Norek, BSN, RN, David M. Foureau, PhD, Carrie Ann Syfert, BSN, RN, Ami P Ndiaye, NP, James T Symanowski, PhD, Jordan Robinson, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-141562

Published: 2020

Journal Articles

Molecular Characterization By Immune Profiling of Paired Blood and Bone Marrow in Multiple Myeloma and Its Precursor States

Manisha Bhutani, MD, David M. Foureau, PhD, Nury M Steuerwald, PhD, Sally Trufan, Fei Guo, PhD, Katherine Rigby, Elise Tjaden, Alicia Hamilton, Marina Leonidas, Aarin Berlin, Laura Johnson, Jordan Williams, Shebli Atrash, Ami P Ndiaye, NP, James Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 4461.

https://doi.org/10.1182/blood-2018-99-118281

Published: 2018

Journal Articles

Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients

David M. Foureau, PhD, Manisha Bhutani, MD, Myra Robinson, MS, Fei Guo, PhD, Duy Pham, Shelley Force Aldred, Ben Buelow, MD PhD, Katherine Rigby, Elise Tjaden, Marina Leonidas, Shebli Atrash, Ami P Ndiaye, NP, James Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 1940.

https://doi.org/10.1182/blood-2018-99-118881

Published: 2018

Journal Articles

Correlation of Myeloid Derived Suppressor Cells and Response to Standard Chemoimmunotherapy in Diffuse Large B Cell Lymphoma

David M. Foureau, PhD, Qing Zhang, PhD, Lawrence J Druhan, PhD, Ryan Jacobs, MD, Fei Guo, PhD, Steven I Park, MD, Danyu Sun, MD PhD, Edward A Copelan, MD, Belinda Rene Avalos, MD, Nilanjan Ghosh, MD PhD

Blood (2017) 130 (Supplement 1): 4023.

https://doi.org/10.1182/blood.V130.Suppl_1.4023.4023

Published: 2017

Journal Articles

Aberrant Trafficking and Signal Propagation By the T618I CSF3R Mutant in Patients with Chronic Neutrophilic Leukemia

Lawrence J Druhan, PhD, Andrea Price, Amanda Lance, Alicia Hamilton, Judy Parsons, MT, Fei Guo, PhD, David M Foureau, PhD, Nury M Steuerwald, PhD, Belinda Rene Avalos, MD

Blood (2017) 130 (Supplement 1): 2941.

https://doi.org/10.1182/blood.V130.Suppl_1.2941.2941

Published: 2017

Journal Articles

Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases

Manisha Bhutani, MD, David M Foureau, PhD, Qing Zhang, PhD, Myra M Robinson, MSPH, Adina Wynn, Nury M Steuerwald, PhD, Lawrence J Druhan, PhD, Fei Guo, PhD, Katherine Rigby, Mitchell Turner, Reed Friend, MD, Shebli Atrash, Ami Ndiaye, Chelsea Sprouse, James T Symanowski, PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD, Peter M. Voorhees, MD, Saad Z Usmani, MD

Blood (2017) 130 (Supplement 1): 3054.

https://doi.org/10.1182/blood.V130.Suppl_1.3054.3054

Published: 2017

Journal Articles

Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

David M Foureau, PhD, Manisha Bhutani, MD, Qing Zhang, PhD, Myra M Robinson, MSPH, Adina Wynn, Nury M Steuerwald, PhD, Lawrence J Druhan, PhD, Fei Guo, PhD, Katherine Rigby, Mitchell Turner, Reed Friend, MD, Shebli Atrash, Chelsea Sprouse, Ami Ndiaye, James T Symanowski, PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD, Peter M. Voorhees, MD, Saad Z Usmani, MD

Blood (2017) 130 (Supplement 1): 1817.

https://doi.org/10.1182/blood.V130.Suppl_1.1817.1817

Published: 2017

Journal Articles

Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma

Myra M Robinson, MSPH, Shebli Atrash, Taylor Brown, BS, MS, Jared G Block, MD, Edward H Lipford, MD, Elton T Smith, MD, Reed Friend, MD, Amanda Aneralla, Alankrita Taneja, MD, Qing Zhang, PhD, David M Foureau, PhD, Chelsea Sprouse, Ami Ndiaye, James T Symanowski, PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD, Peter M. Voorhees, MD, Saad Z Usmani, MD, Manisha Bhutani, MD

Blood (2017) 130 (Supplement 1): 4348.

https://doi.org/10.1182/blood.V130.Suppl_1.4348.4348

Published: 2017

NARROW

Myeloid Derived Suppressor Cell Kinetics in Peripheral Blood Correlate with Efficacy and Toxicity of CAR T Cell Therapy in Relapsed or Refractory B Cell Lymphoma

The Novel CDK9/CDK4/6/PI3K Triple Inhibitor LCI139 for the Treatment of MYC -Driven Mantle Cell Lymphoma

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study

Aurora Kinase Inhibition Overcomes Primary Venetoclax Failure and Leads to Synthetic Lethality in BCL2-Positive Lymphomas Via Upregulation of P53/P21/BAX Axis

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Central Memory T-Cell Differentiation Correlates with Depth of Response in Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone (Elo-KRd)

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Molecular Characterization By Immune Profiling of Paired Blood and Bone Marrow in Multiple Myeloma and Its Precursor States

Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients

Correlation of Myeloid Derived Suppressor Cells and Response to Standard Chemoimmunotherapy in Diffuse Large B Cell Lymphoma

Aberrant Trafficking and Signal Propagation By the T618I CSF3R Mutant in Patients with Chronic Neutrophilic Leukemia

Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases

Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only